Interstitial Lung Disease
The Alfred has been at the centre of research driving change in the treatment of interstitial lung disease.
The clearest example of this has been in the approach to idiopathic pulmonary fibrosis, the commonest and one of the most devastating of presentations seen in The Alfred's Interstitial Lung Disease Clinic. Previously, there was no evidence based therapy for this condition and it carried a prognosis of approximately three years survival from the time of diagnosis.
The Monash-Alfred team contributed to the authorship of studies published in The New England Journal of Medicine demonstrating that two molecules were able to halve the rate of progression of idiopathic pulmonary fibrosis, in addition to demonstrating a number of other benefits associated with efficacy. The Alfred's interstitial lung disease team, headed by Adjunct Clinical Associate Professor Ian Glaspole, carries out research that has been both nationally and internationally recognised.
These include being the Victorian centre for the Australian Idiopathic Pulmonary Fibrosis Registry, the home of a tissue biobank for interstitial lung disease and Australia's longest running interstitial lung disease clinic. Numerous basic, translational and clinical science projects are based upon these efforts and have spawned three successful NHMRCfunded research projects in the last few years.